Demographics of patients and sibling donors
| Characteristics . | No. . | % . |
|---|---|---|
| Patients, n = 111 | ||
| Age, y | ||
| Median | 49.05 | |
| Range | 19-72 | |
| Male sex | 51 | 45.9 |
| Karnofsky performance score | ||
| Median | 90 | |
| Range | 70-100 | |
| Diagnosis | ||
| AML | 111 | 100 |
| Myeloablative conditioning | ||
| Busulfan/cyclophosphamide | 61 | 55 |
| Cyclophosphamide/TBI | 36 | 32.5 |
| Fludarabine/treosulfan | 14 | 12.5 |
| GVHD prophylaxis | ||
| Tacrolimus/MTX | 85 | 76.5 |
| Cyclosporine/MMF | 16 | 14.4 |
| Cyclosporine/MTX | 10 | 9.1 |
| Average GVHD onset, d | ||
| Cyclosporine | 29 | |
| Range | 0-95 | |
| Donors, n = 111 | ||
| Age, y | ||
| Median | 47.5 | |
| Range | 24-79 | |
| Male sex | 45 | 40.5 |
| Stem cell product | ||
| Peripheral blood | 91 | 81.9 |
| Bone marrow | 20 | 18.1 |
| AAT plasma levels, mg/mL | ||
| Mean | 3.31 | |
| Range | 0.4-12.5 |
| Characteristics . | No. . | % . |
|---|---|---|
| Patients, n = 111 | ||
| Age, y | ||
| Median | 49.05 | |
| Range | 19-72 | |
| Male sex | 51 | 45.9 |
| Karnofsky performance score | ||
| Median | 90 | |
| Range | 70-100 | |
| Diagnosis | ||
| AML | 111 | 100 |
| Myeloablative conditioning | ||
| Busulfan/cyclophosphamide | 61 | 55 |
| Cyclophosphamide/TBI | 36 | 32.5 |
| Fludarabine/treosulfan | 14 | 12.5 |
| GVHD prophylaxis | ||
| Tacrolimus/MTX | 85 | 76.5 |
| Cyclosporine/MMF | 16 | 14.4 |
| Cyclosporine/MTX | 10 | 9.1 |
| Average GVHD onset, d | ||
| Cyclosporine | 29 | |
| Range | 0-95 | |
| Donors, n = 111 | ||
| Age, y | ||
| Median | 47.5 | |
| Range | 24-79 | |
| Male sex | 45 | 40.5 |
| Stem cell product | ||
| Peripheral blood | 91 | 81.9 |
| Bone marrow | 20 | 18.1 |
| AAT plasma levels, mg/mL | ||
| Mean | 3.31 | |
| Range | 0.4-12.5 |